智通财经APP获悉，华领医药-B(02552)涨超14%，盘中高见4.7港元创2023年2月以来新高。截至发稿，涨14%，报4.56港元，成交额1.82亿港元。
消息面上，近日，华领医药公布2025年中期业绩。报告期内，华堂宁®销量达176.4万盒，同比增长108%，净销售额2.174亿元，同比增长112%。值得一提的是，与拜耳终止独家推广服务协议后，公司确认一次性递延收入12.435亿元，上半年实现盈利11.839亿元，首次在业绩期内盈利，标志着其商业化转型成效显著。同时，生产规模扩大与运营效率提升推动毛利率升至54.2%，同比增长7.7个百分点，盈利向好趋势明显。
此外，华领医药正积极拓展海外业务，加速全球化布局。公司已向中国香港递交多格列艾汀75mg(商品名：华领片®，MYHOMSISTM)的注册申请，此举将加速其在大中华区及东南亚市场的布局。不仅如此，基于美国I期单剂量递增研究的初步成功，公司计划于2025年底或2026年初启动多剂量递增I期研究，持续推动第二代GKA在全球市场的业务发展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.